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Abstract
Background: Ambulatory blood pressure monitoring (ABPM) shows a better correlation to target organ damage
and cardiovascular morbidity-mortality than office blood pressure. A loss of arterial elasticity and an increase in
carotid artery intima-media thickness (IMT) has been associated with increased cardiovascular morbidity-mortality.
Tools have been developed that allow estimation of the retinal arteriovenous index but not all studies coincide
and there are contradictory results in relation to the evolution of the arteriosclerotic lesions and the caliber of the
retinal vessels. The purpose of this study is to analyze the relationship between peripheral and central arterial
pressure (clinic and ambulatory) and vascular structure and function as evaluated by the carotid artery intima-
media thickness, retina arteriovenous index, pulse wave velocity (PWV) and ankle-brachial index in patients with
and without type 2 diabetes. In turn, software is developed and validated for measuring retinal vessel thickness
and automatically estimating the arteriovenous index.
Methods/Design: A cross-sectional study involving a control group will be made, with a posterior 4-year follow-up
period in primary care. The study patients will be type 2 diabetics, with a control group of non-diabetic individuals.
Consecutive sampling will be used to include 300 patients between 34-75 years of age and no previous
cardiovascular disease, one-half being assigned to each group. Main measurements: age, gender, height, weight
and abdominal circumference. Lipids, creatinine, microalbuminuria, blood glucose, HbA1c, blood insulin, high
sensitivity C-reactive protein and endothelial dysfunction markers. Clinic and ambulatory blood pressure
monitoring. Carotid ultrasound to evaluate IMT, and retinography to evaluate the arteriovenous index. ECG to
assess left ventricle hypertrophy, ankle-brachial index, and pulse wave analysis (PWA) and pulse wave velocity
(PWV) with the Sphigmocor System.
Discussion: We hope to obtain information on the correlation of different ABPM-derived parameters and PWA to
organ target damage - particularly vascular structure and function evaluated from the IMT and PWV - and
endothelial dysfunction in patients with and without type 2 diabetes. We also hope to demonstrate the usefulness
of the instrument developed for the automated evaluation of retinal vascularization in the early detection of
alterations in vascular structure and function and in the prognosis of middle-term cardiovascular morbidity.
Trial Registration: Clinical Trials.gov Identifier: NCT01325064
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Blood pressure measurement at the clinic remains the
standard of reference, but there are increasing evidence
that the values obtained after home blood pressure mea-
surement by the patient and particularly 24-hour ambu-
latory blood pressure monitoring (ABPM) [1] shows a
better correlation to target organ damage and cardiovas-
cular morbidity-mortality [2-4]. The prognostic value of
resting blood pressure, particularly when the latter
decreases, is greater than that of blood pressure during
activity [5,6]. On the other hand, the ambulatory arterial
stiffness index (AASI) [7] is a better estimator of central
arterial stiffness than other classical indicators such as
pulse pressure (PP) [8], and has been shown to be a use-
ful predictor of vascular mortality, particularly in fatal
and nonfatal stroke [9,10].
A loss of arterial elasticity, or arterial stiffness, has
been associated with increased cardiovascular morbid-
ity-mortality. At present the gold standard for evaluat-
ing arterial stiffness is carotid-femoral pulse wave
velocity [11]. This parameter has been related to
increased morbidity-mortality in both patients with
cardiovascular disease and in healthy subjects [12,13].
It has also been observed that central arterial pressure
is more strongly correlated to cardiovascular morbid-
ity-mortality than peripheral arterial pressure [14]. In
t h eA S C O Ts t u d y[ 1 5 ] ,i n c r e a s e dm o r b i d i t ya n dm o r -
tality was found in one of the study groups compared
to the other, despite the fact that the peripheral arter-
ial pressures were similar in both groups. In the CAFÉ
sub-study [16] the subjects with increased morbidity-
mortality were found to have greater central arterial
pressure and a higher augmentation index (AIx)
(defined as the ratio between the increase in central
systolic pressure and central pulse pressure) than the
other group. The serum levels of osteoprotegerin
(OPG) are elevated in patients with type 1 and 2 dia-
betes, representing an early marker contributing to the
endothelial dysfunction associated with the disease. In
addition, OPG concentration in plasma is correlated to
the severity of peripheral arterial disease [17]. An
increase in carotid artery intima-media thickness
(IMT) is an early phenomenon in the development of
arteriosclerosis. A number of studies in asymptomatic
individuals have shown carotid IMT to be an indepen-
dent risk factor for coronary disease and stroke
[18-20].
The classical Keith Wagener classification applied to
the analysis of retinal vascular lesions has some limita-
tions, particularly in correctly evaluating the initial
phases of the vascular lesions. Tools have been devel-
oped that allow estimation of the retinal arteriovenous
index [18,20-23], and this index and arterial and
venous caliber independently have been correlated to
an increased risk of arterial hypertension, diabetes
mellitus and cardio and cerebrovascular diseases
[24-27]. However, not all studies coincide, and there
are contradictory results in relation to the evolution of
the arteriosclerotic lesions and the caliber of the ret-
inal vessels. In addition, the existing tools are manual
or semiautomated, and observer influence conse-
quently can prove important. The development of
automated tools designed to improve performance and
lessen interobserver variability therefore appears
necessary.
In a phase prior to this project we developed a tool
that determines retinal artery and vein thickness and
estimates the retina arteriovenous index based on a
semiautomated method, with the purpose of obtaining
an automatic tool for this study. Associated cardiovascu-
lar disorders are the main cause of mortality in diabetic
patients [28]. Patients with diabetes mellitus show pre-
mature vascular aging compared with the non-diabetic
population. This increases their vascular risk two- to
three-fold in men and four- to five-fold in women,
according to the European cardiovascular prevention
guide of 2007, compared with the population without
diabetes [29]. This makes it extremely important to
ensure the early detection of arterial stiffness in this
population, in order to adopt the opportune measures
to lessen cardiovascular risk. Lastly, the correlation of
central arterial pressure, the augmentation index (AI),
pulse wave velocity (PWV) and AASI to target organ
damage in diabetics has not been explored in depth.
Likewise, the correlation to the retina arteriovenous
index has not been specifically established to date. It is
also necessary to better establish the prognostic value of
central arterial pressure and PWV in relation to the evo-
lution of the target organ damage markers and to the
possible incidence of cardiovascular events in patients
with type 2 diabetes.
The present project was therefore designed to analyze
the relationship between arterial pressure (clinic and
ambulatory), the arterial pressure circadian profile and
other parameters generated by ABPM and central arter-
ial pressure, and vascular structure and function as eval-
uated by the carotid IMT, retina arteriovenous index,
PWV and ankle-brachial index (ABI) in patients with
and without type 2 diabetes.
An evaluation also will be made of the prognostic use-
fulness of the retina arteriovenous index in relation to
the presence of vascular damage and cardiovascular dis-
ease, and to biological markers of endothelial dysfunc-
tion. To this effect an automated tool will be developed
for estimating retinal artery and vein calibers, and for
calculating the retina arteriovenous index.
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Study design
The first phase will comprise a cross-sectional observa-
tional study with a control group, while the second
phase will consist of a prospective observational study
with annual follow-up during four years. The study will
be carried out in the urban primary care setting.
Subjects
The study population will be composed of type 2 dia-
betics, and an age- and gender-matched control group
without diabetes will also be included. Based on conse-
cutive sampling of all patients referred to the research
unit for cardiovascular risk assessment, we will invite
those who meet the inclusion criteria and show no rea-
sons for exclusion to participate in the study, until the
estimated sample sizes of both groups have been
reached.
Inclusion criteria: Patients aged 34 years or older and
less than 75 years, with and without type 2 diabetes.
Exclusion criteria: patients unable to comply with the
protocol requirements (psychological and/or cognitive
disorders, failure to cooperate, educational limitations
and problems for understanding), patients with ischemic
heart disease, cerebrovascular disease or other athero-
sclerotic disease, patients participating or who will parti-
cipate in a clinical trial during the study, and patients
with serious comorbidities representing a threat to life
over the subsequent 12 months.
T h es a m p l es i z ew a se s t i m a ted to detect differences
between the subjects with and without diabetes in refer-
ence to PWV, as this represents the most unfavorable
situation. Accepting an alpha risk of 0.05 and a beta risk
of 0.20 in two-sided contrasts, 149 subjects are required
in the first group and 149 in the second, in order to
detect a difference of ≥ 1 unit. The common standard
deviation (SD) is taken to be 3 [30], with a potential 5%
rate of losses or difficulties in the technique. This sam-
ple suffices to detect a difference of 0.01 units in the
retina arteriovenous index, considering a SD of 0.028
[23] and losses due to difficulties in the technique of
10%. Accepting an alpha risk of 0.05 and a beta risk of
0.20 in two-sided contrasts, 137 subjects are required in
the first group and 137 in the second. Thus, we aim to
include 300 patients: one-half diabetics and the other
half without diabetes.
Variables and measurement instruments
Demographic and clinical variables
Age and gender. Family history of cardiovascular dis-
ease. Associated cardiovascular diseases, arterial hyper-
tension, dyslipidemia, diabetes mellitus. History of
smoking, alcohol consumption and physical activity.
Arterial pressure and heart rate in clinic and with
ABPM. Height, weight, and abdominal (waist) circum-
ference. Blood sampling will be carried out under fasting
conditions, and first morning urine will be collected. A
blood sample and the urine will be sent to the core
laboratory, and another blood sample will be centrifuged
and frozen for posterior analysis. Initial determination
will be made of blood glucose, HbA1c, insulinemia,
microalbuminuria, blood and urine creatinine, lipids and
high sensitivity C-reactive protein. Posteriorly, biological
markers of endothelial dysfunction will be determined
(endoglin and osteoprotegerin, OPG).
The office blood pressure and heart rate measure-
ment will be obtained by performing three measure-
ments of systolic blood pressure (SBP) and diastolic
blood pressure (DBP), with a validated sphygmoman-
ometer, OMRON M7 model (Omron Health Care,
Kyoto, Japan), following the recommendations of the
European Society of Hypertension [31]. The mean of
the last two measurements obtained from the arm with
high blood pressure by the nurse of the research unit
will be used for the study.
T h eA m b u l a t o r yb l o o dp r e s s u r em o n i t o r i n g
(ABPM) and heart rate will be performed on a day of
standard activity, with an adequate cuff for the size of
the patient’s arm. A SpaceLabs 90207 control system
(Spacelabs Healthcare, Issaquah, Washington, USA),
validated according to the protocol of the British Hyper-
tension Society, was used [32]. The records of readings
considered to be valid will be ≥ 66% of the total.
Furthermore, for the records to be evaluable, at least 14
measurements were required during the daytime period,
or at least 7 during the nighttime or rest period. The
monitor will be programed for obtaining blood pressure
measurements every 20 min. during the daytime period
and every 30 min. during the rest period.
Ambulatory arterial stiffness index (AASI) will be
defined as 1 minus the regression slope of DBP over
SBP readings obtained from individual 24-hour blood
pressure recordings The stiffer the arterial tree will be
the closer the regression slope and AASI will be to 0
and 1, respectively [33].
P u l s ew a v ev e l o c i t y( P W V )a n dP e r i p h e r a l( P A I x )
and central (CAIx) Augmentation Index will be esti-
mated through the SphymgoCor System (AtCor Medical
Pty Ltd Head Office, West Ryde, Australia). Using the
SphygmoCor System (Px Pulse Wave Analysis) by an
investigator, with the patient in the sitting position and
resting the arm on a rigid surface, pulse wave analysis
will be made with a sensor in the radial artery, using
mathematical transformation to estimate the aortic
pulse wave. The reliability of which was evaluated before
the study began using the intra-class correlation coeffi-
cient showed values of 0.977 (95%CI: 0.942 to 0.991) for
inter-observer agreement and 0.979 (95%CI: 0.948 to
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surements in 20 subjects, and according to the Bland-
Altman analysis the limit of intra-observer agreement
was 0.650 (-6.496 to 7.796) and inter-observer agree-
ment was 1.250 (-5.914 to 8.414). From the morphology
of the aortic wave, Central AIx will be estimated using
the following formula: Increase in central pressure *
100/pulse pressure. Peripheral AIx will be calculated as
follows: (Second peak systolic blood pressure [SBP2]-
diastolic blood pressure [DBP])/(first peak SBP-
DBP)×100(%). Using the SphygmoCor System (Vx Pulse
Wave Velocity), and with the patient in the supine posi-
tion, the pulse wave of the carotid and femoral arteries
will be analyzed, estimating the delay with respect to the
ECG wave and calculating the PWV. Distance measure-
ments will be taken with a measuring tape from the
sternal notch to the carotid and femoral arteries at the
sensor location.
Assessment of carotid intima-media thickness (IMT)
Carotid ultrasonography to assess IMT will be per-
formed by two investigators trained for this before start-
ing the study. The reliability of which was evaluated
before the study began using the intraclass correlation
coefficient, which showed values of 0.974 (95%CI: 0.935
to 0.990) for intra-observer agreement on repeated mea-
surements in 20 subjects, and 0.897 (95%CI:0.740 to
0.959) for inter-observer agreement, and according to
the Bland-Altman analysis, the limit of inter-observer
agreement was 0.022 (-0.053 to 0.098) and the limit of
intra-observer agreement was 0.012 (-0.034 to 0.059). A
Sonosite Micromax ultrasound device paired with a 5-
10 Mhz multifrequency high-resolution linear transdu-
cer with Sonocal software will be used for performing
automatic measurements of IMT in order to optimize
reproducibility. Measurements will be made of the com-
mon carotid after the examination of a longitudinal sec-
tion of 10 mm at a distance of 1 cm from the
bifurcation, performing measurements in the anterior or
proximal wall, and in the posterior or distal wall in the
lateral, anterior and posterior projections, following an
axis perpendicular to the artery to discriminate two
lines, one for the intima-blood interface and the other
to the media-adventitious interface. A total of 6 mea-
surements will be obtained of the right carotid and
other 6 of the left carotid, using average values (average
IMT) and maximum values (maximum IMT) calculated
by the software automatically. The measurements will
be obtained with the subject lying down, with the head
extended and slightly turned opposite to the carotid
examined, following the recommendations of the Man-
heim Carotid Intima-Media Thickness Consensus [34].
Evaluation of peripheral artery involvement
This will be evaluated using the ankle-brachial index
(ABI), performed in the morning without having
consumed coffee or tobacco for at least 8 hours prior to
measuring and an ambient temperature of 22-24°C.
With the feet uncovered, in a supine decubitus position
after 20 minutes of rest, the pressure in the lower extre-
mities and blood pressure in both arms will be mea-
sured using a portable WatchBP Office ABI (Microlife
AG Swiss Corporation).The ABI will be calculated auto-
matically for each foot by dividing the higher of the two
systolic pressures in the ankle by the highest measure-
ment of the two systolic pressures in the arm [35].
Cardiac assessment
The electrocardiographic examination will be performed
with a General Electric MAC 3.500 ECG System (Nis-
kayuna, New York, USA), that measures automatically
the voltage and duration of waves and estimates the cri-
teria of the Cornell voltage-duration product (Cornell
VDP) to assess the LVH by the following equation: Men
((RaVL + SV3) * QRS) and women ((RaVL + SV3) *
QRS + 6). LVH is defined as the voltage-duration pro-
duct > 2,440 mm/ms [36]. We will estimate left ventri-
cular mass index (LVMI) by Novacode equation [37].
Renal assessment
The kidney damage will be assessed by measuring crea-
tinine plasma concentration, the glomerular filtration
rate will be estimated by CKD-EPI (Chronic Kidney Dis-
ease Epidemiology Collaboration) [38] and the MDRD-
IDMS (Modification of Diet in Renal Disease-Isotopic
Dilution Mass Spectrometry) [39] equation and protei-
nuria will be assessed by the albumin/creatinine ratio
following the 2007 European Society of Hypertension/
European Society of Cardiology Guidelines criteria [40].
Subclinical organ damage will be defined as plasma
creatinine between 1.3 - 1.5 mg/dl in men and 1.2 - 1.4
mg/dl in women, glomerular filtration rate below 60 ml/
min or albumin/creatinine ratio > 22 mg/gr in men and
31 mg/gr in women. Renal disease will be defined as
plasma creatinine of 1.5 mg/dl or higher in men and 1.4
mg/l in women or albumin/creatinine ratio > 300 mg/
24h.
Evaluation of retinal involvement
Retinography will be performed with a Topcon TRC
NW 200 non-mydriatic retinal camera (Topcon Europe
B.C. Capelle a/d IJssel The Netherlands), obtaining
images centered on the papilla, nasal and temporal.
Once the images will be captured, two independent
observers classified them according to the Keith-Wage-
ner and Wong classification for hypertensive retinopathy
[41,42], and serious international scale for diabetic reti-
nopathy with a third reading being performed in cases
where there were discrepancies. Grades III or IV
(hemorrhages or exudates, papillary edema) are consid-
ered to be associated with cardiovascular disease [40].
As part of the project we include development of the
second phase of software designed to semiautomatically
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CRAE) and venous caliber (central retinal vein equiva-
lent, CRVE) of the retinal vascular tree and to automati-
cally estimate the retina arteriovenous index, based on a
method similar to that of the Atherosclerosis Risk in
Communities (ARIC) study in the United States [43],
making it possible to increase measurement precision
and minimize interobserver variability. In this second
phase we aim to automatize the software in order to
avoid interobserver variability, and increase the effi-
ciency of retinal evaluation so that the retinas are auto-
matically evaluated by the developed tool and a final
report is generated with the measurements made.
Validation of the retina software
For validation of the retina software in its semiauto-
mated and automated versions, the following steps will
be followed after prior training of the examiners who
will evaluate the images obtained: 1.- Intraobserver
variability: in order to assess the repeatability of the
measurement, an operator must measure the same
photograph in the same individual at least twice. To this
effect, an operator will evaluate 200 images of a random
sub-sample of 100 patients, with a difference of one
week between the two evaluations. In this case the
operator and the images analyzed will be the same on
both days, and the operator will have no information on
the previously performed evaluation. 2.- Interobserver
variability: in order to assess the reproducibility of the
measurement system, an operator different from that in
phase 1 will evaluate the same 200 images previously
analyzed. This operator will be blinded to the results
already obtained in the previous phase. The two opera-
tors will have the same experience in the subject and in
the use of the software, and both will receive the same
prior training. 3.- Ocular variability: one month later,
new photographs will be obtained of the same group of
patients. These results will be evaluated by the operator
of phase 1, and in this case the origin of the image, the
patient characteristics and the results obtained in the
previous evaluation will not be known. 4.- Furthermore,
the retina software in its automated version (phase 2)
generates the results relating to the retina arteriovenous
index, CRAE and CRVE. In the semiautomated version
the user participates and decides the interpretations
made by the computer, and can change them if consid-
ered necessary. The automatic and semiautomatic eva-
luation of 200 images will be used to assess the degree
of concordance between the two methodologies. In this
way we will be able to show that the automatic method
not only affords the same results but moreover also
improves daily practice, affording greater objectivity and
speed in producing the results. 5.- The validity of the
measurement will be analyzed comparing the results
with the carotid IMT as measure of vascular structure
and with PWV as measure of vascular function and gold
standard of arterial stiffness of the 300 patients included
in the study. 6.- An analysis also will be made of the
association of the estimated retina arteriovenous index
and the evolution or appearance of new target organ
damage and cardiovascular events during follow-up of
the patients over the four years of the second phase of
this project.
Statistical analysis
The data will be presented with the mean and 95% con-
fidence interval (95%CI) in the case of quantitative vari-
ables, and as frequency distributions for qualitative
variables. The Pearson chi-squared test will be used to
analyze associations between qualitative variables. Stu-
dent’s t test for independent samples will be used to
compare the means of two groups, and analysis of var-
iance (ANOVA) will be performed in the case of a lar-
g e rn u m b e ro fg r o u p s .Post hoc contrasts will be made
with the least significant difference (LSD) technique,
with an alpha < 0.05. The relationship between quantita-
tive variables will be analyzed using Pearson’s correla-
tion coefficient. Estimation of the slope of the straight
line needed to calculate the ambulatory arterial stiffness
index (AASI) will be made based on a linear regression
model. Lastly, multiple linear regression and logistic
regression analysis will be made to analyze the most sig-
nificant variables conditioning the alterations in arterial
pressure and vascular damage with the different meth-
odologies used in the two groups. Hypothesis contrast-
ing will establish an alpha risk factor of 0.05 as the limit
of statistical significance.
Validation of the retina software: For evaluating the
measurements of the retina arteriovenous index, CRAE
and CRVE obtained in the three validation phases, cal-
culation will be made of the intraclass correlation coeffi-
cient as comparison method, together with the Bland-
Altman technique, which allows graphical evaluation of
the concordance or agreement between the two mea-
surement systems. The results obtained with the two
types of measurements that can be made with the soft-
ware (automated or semiautomated) will be analyzed
with the intraclass correlation coefficient and Kappa
concordance coefficient on categorizing the variable.
This coefficient will allow us to evaluate the degree of
concordance between the two types of results. The
SPSS/PC+ version 18.0 statistical package will be used.
Study limitations
The sample is composed of diabetics and non-diabetics,
many of them with arterial hypertension referred by
their primary care physician to the research unit for
ABPM and the evaluation of cardiovascular risk. As a
result, consecutive non-randomized sampling is
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offsets this limitation, and the real clinical practice con-
ditions can bring us closer to the real-life situation than
if more restrictive criteria were used for including the
patients in the study. We will have diabetic, hypertensive
and control subjects without these disorders for analysis
and comparison of the results.
Quality control
In order to ensure data quality, the nursing professionals
in charge of data collection will receive specific training.
Periodic external monitoring will be performed to verify
adequate application of the methodology, both in per-
forming the different examinations and in collecting the
information.
Ethical and legal issues
In order to guarantee data confidentiality, all the elec-
tronic and paper copies of the protocol, signed informed
consent documents and results of the tests made in
each of the patients will be kept locked in a safe place,
and only the study investigators will have access to the
data on the subjects who agree to participate in the
study. The study has been approved (Agost 10, 2010) by
the research ethics committee from University Hospital
of Salamanca, Spain and complies with Spanish data
protection law 15/1999 and its recently developed speci-
fications (Royal Decree (RD) 1720/2007). Knowledge
and agreement to cooperate has been established with
the implicated services, signed by the legal representa-
tive of the centre. Written informed consent to partici-
pation in the study will be obtained in all cases.
Discussion
The measurement of arterial pressure, both in the clinic
and on an ambulatory basis, is very widespread in clini-
cal practice, and its direct correlation to mortality and
morbidity has been extensively studied [44-46]. How-
ever, the correlation of other parameters derived from
ABPM and central arterial pressure with cardiovascular
target organ damage, and the behavior of diabetic
patients versus non-diabetic individuals, have not been
fully clarified. With this stu d yw eh o p et oo b t a i ni n f o r -
mation on the correlation of parameters such as the
night/day arterial pressure ratio, AASI, symmetrical
AASI, variability of arterial pressure and heart rate and
other parameters to be defined with organ target
damage - particularly vascular structure and function
evaluated from the IMT and PWV - and endothelial
dysfunction as assessed by biological parameters. Like-
wise, there are a series of parameters derived from pulse
wave analysis (PWA) such as the central and peripheral
augmentation index, whose role as predictors of cardiac
or renal vascular damage and behavior in different
groups of patients (e.g., diabetics versus non-diabetics)
have not been fully clarified. In this sense, we hope to
obtain sufficient information to clarify the role of these
parameters.
We also hope to demonstrate the usefulness of the
instrument developed for the automatic evaluation of
retinal vascularization in the early detection of altera-
tions in vascular structure and function and in the prog-
nosis of middle-term cardiovascular morbidity. This tool
could help improve the information derived from retinal
photographs and make their use more efficient thanks
to automatization of the procedures, in both diabetics
and in individuals without diabetes. Lastly, we hope to
clarify the prognostic role of the biological markers of
endothelial dysfunction such as osteoprotegerin and
endoglin, and to standardize their use in clinical
practice.
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